Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8852955 | 0.91 | CYP3A4 (0.44) | CYP3A4MAPK1TSHRUSP2CYP1A2 | |
| SCHEMBL9598060 | 0.71 | CYP3A4 (0.43) | CYP3A4TSHRUSP2CYP1A2CYP2C9 | |
| SCHEMBL14369404 | 0.70 | ESR1 (0.41) | CYP3A4MAPK1TSHRCYP1A2MEN1 | |
| SCHEMBL4852108 | 0.70 | FFAR3 (0.41) | TSHRCYP2C19 | |
| SCHEMBL24248777 | 0.70 | CYP3A4 (0.36) | CYP3A4MAPK1TSHRUSP2CYP1A2 | |
| SCHEMBL7575320 | 0.69 | MAPK1 (0.39) | CYP3A4MAPK1TSHRMEN1KMT2A | |
| SCHEMBL16415664 | 0.69 | FFAR3 (0.39) | TSHRCYP2C19 | |
| SCHEMBL14930639 | 0.69 | USP2 (0.42) | CYP3A4MAPK1TSHRUSP2CYP1A2 | |
| SCHEMBL24249342 | 0.68 | CYP3A4 (0.38) | CYP3A4USP2CYP1A2CYP2C9MEN1 | |
| SCHEMBL16468545 | 0.67 | CTSK (0.42) | TSHRUSP2MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4333907-A2 | MIRNA INHIBITORS FOR PREVENTING AND TREATING ANEURYSMS, HYPERTENSION, ARDS AND OTHER DISEASES ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION | The Regents of the University of California (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022236161-A2 | MIRNA INHIBITORS FOR PREVENTING AND TREATING ANEURYSMS, HYPERTENSION, ARDS AND OTHER DISEASES ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20210278391-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR AND METABOLIC CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-09-09 | — | — | US | disclosed |
| WO-2018144700-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR AND METABOLIC CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | WO | disclosed |
| US-9233164-B2 | Water soluble fullerene formulations and methods of use thereof | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2016-01-12 | — | — | US | disclosed |
| US-20130323188-A1 | Water Soluble Fullerene Formulations and Methods of Use Thereof | BOARD OF THE REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2013-12-05 | — | — | US | disclosed |
| WO-2012097245-A1 | WATER SOLUBLE FULLERENE FORMULATIONS AND METHODS OF USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2012-07-19 | — | — | WO | disclosed |
| US-20060276385-A1 | Anti-inflammatory agents and methods of their use | JO HANJOONG | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130323188-A1 | Water Soluble Fullerene Formulations and Methods of Use Thereof | TP53, SLC46A1, SLC40A1 | CYP3A4 2066/4885MAPK1 4808/4885TSHR 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.